403 related articles for article (PubMed ID: 33374804)
1. The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time's a Charm.
Lecocq Q; Keyaerts M; Devoogdt N; Breckpot K
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374804
[TBL] [Abstract][Full Text] [Related]
2. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target.
Qian W; Zhao M; Wang R; Li H
J Hematol Oncol; 2021 Sep; 14(1):147. PubMed ID: 34526102
[TBL] [Abstract][Full Text] [Related]
3. Lymphocyte-activation gene-3, an important immune checkpoint in cancer.
He Y; Rivard CJ; Rozeboom L; Yu H; Ellison K; Kowalewski A; Zhou C; Hirsch FR
Cancer Sci; 2016 Sep; 107(9):1193-7. PubMed ID: 27297395
[TBL] [Abstract][Full Text] [Related]
4. Blockade of LAG-3 in PD-L1-Deficient Mice Enhances Clearance of Blood Stage Malaria Independent of Humoral Responses.
Furtado R; Chorro L; Zimmerman N; Guillen E; Spaulding E; Chin SS; Daily JP; Lauvau G
Front Immunol; 2020; 11():576743. PubMed ID: 33519801
[TBL] [Abstract][Full Text] [Related]
5. Second- and third-generation drugs for immuno-oncology treatment-The more the better?
Dempke WCM; Fenchel K; Uciechowski P; Dale SP
Eur J Cancer; 2017 Mar; 74():55-72. PubMed ID: 28335888
[TBL] [Abstract][Full Text] [Related]
6. Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer.
Jung EH; Jang HR; Kim SH; Suh KJ; Kim YJ; Lee JH; Chung JH; Kim M; Keam B; Kim TM; Kim DW; Heo DS; Lee JS
Thorac Cancer; 2021 Mar; 12(5):619-630. PubMed ID: 33458968
[TBL] [Abstract][Full Text] [Related]
7. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the expression of the immune checkpoint molecules PD-1, CTLA4, TIM-3 and LAG-3 across different cancers in relation to treatment response, tumor-infiltrating immune cells and survival.
Tu L; Guan R; Yang H; Zhou Y; Hong W; Ma L; Zhao G; Yu M
Int J Cancer; 2020 Jul; 147(2):423-439. PubMed ID: 31721169
[TBL] [Abstract][Full Text] [Related]
9. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade.
Zuo S; Wei M; Xu T; Kong L; He B; Wang S; Wang S; Wu J; Dong J; Wei J
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949694
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoints and cancer development: Therapeutic implications and future directions.
Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
[TBL] [Abstract][Full Text] [Related]
11. LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors.
Burugu S; Gao D; Leung S; Chia SK; Nielsen TO
Ann Oncol; 2017 Dec; 28(12):2977-2984. PubMed ID: 29045526
[TBL] [Abstract][Full Text] [Related]
12. Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy.
Qi Y; Chen L; Liu Q; Kong X; Fang Y; Wang J
Front Immunol; 2020; 11():563258. PubMed ID: 33488573
[TBL] [Abstract][Full Text] [Related]
13. PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma.
Tobin JWD; Bednarska K; Campbell A; Keane C
Cells; 2021 May; 10(5):. PubMed ID: 34068762
[TBL] [Abstract][Full Text] [Related]
14. On the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment.
Tundo GR; Sbardella D; Lacal PM; Graziani G; Marini S
Chemotherapy; 2019; 64(2):62-80. PubMed ID: 31387102
[TBL] [Abstract][Full Text] [Related]
15. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
16. Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma.
El Halabi L; Adam J; Gravelle P; Marty V; Danu A; Lazarovici J; Ribrag V; Bosq J; Camara-Clayette V; Laurent C; Ghez D
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):257-266.e3. PubMed ID: 33277223
[TBL] [Abstract][Full Text] [Related]
17. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.
Ma W; Gilligan BM; Yuan J; Li T
J Hematol Oncol; 2016 May; 9(1):47. PubMed ID: 27234522
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.
Sasidharan Nair V; El Salhat H; Taha RZ; John A; Ali BR; Elkord E
Clin Epigenetics; 2018; 10():78. PubMed ID: 29983831
[TBL] [Abstract][Full Text] [Related]
19. Understanding LAG-3 Signaling.
Chocarro L; Blanco E; Zuazo M; Arasanz H; Bocanegra A; Fernández-Rubio L; Morente P; Fernández-Hinojal G; Echaide M; Garnica M; Ramos P; Vera R; Kochan G; Escors D
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34067904
[TBL] [Abstract][Full Text] [Related]
20. Personalized Immuno-Oncology.
Jain KK
Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]